Book a Meeting

Non-IgG Therapeutic Antibodies Discovery

More Info
Background Our Service Highlights FAQs Published Data Resource

Non-IgG Therapeutic Antibodies Discovery As a senior biotech company dedicated to promoting human health research, Creative Biolabs has bent ourselves to non-IgG antibodies development for several years in order to discover more efficient therapeutic molecules. We are now proud and pleased to provide a wide range of products and services of non-IgG therapeutic antibodies to global customers.


Introduction to Therapeutic Antibodies

Therapeutic antibodies, specifically refer to monoclonal antibodies, are bioactive antibodies with the ability to attack specific cells or proteins for the treatment of a wide variety of diseases, including cancers, immune disorders, and infections. Therapeutic antibodies have been flourishingly developing since the first therapeutic antibody, Muromonab-CD3, was approved by the Food and Administration (FDA) as an immunosuppressive agent in 1986. By early 2019, over 4,000 therapeutic antibodies in different phases have been recorded by Therapeutic Antibody Database, among which about 100 antibodies have been approved by the FDA for diseases treatment. However, the overwhelming majority of these therapeutic antibodies (nearly 5,000) are IgG isotype antibodies, only 12 and 2 antibodies are IgM and IgA isotypes respectively, and even no IgD and IgE isotypes.

Why Are the Discovery and Development of Non-IgG Therapeutic Antibodies Hampered?

The involved reasons may include but not limited to:

  1. The production of non-IgG antibodies (mainly IgA) is different and difficult compared to IgG antibodies, which can’t be obtained by traditional hybridoma techniques.
  2. Extremely low abundance of IgD and IgE.
  3. Non-IgG antibodies purification by conventional technologies is limited by several factors, such as incapability of IgD and IgE to bind to Protein A/G, narrow solubility, poor stability and binding of IgM to protein A/G.
  4. Some non-IgG antibodies isotypes/sub-isotypes in humans are different from those experimental animals (e.g. commonly used rodents).
  5. Ideal well-established animal models are lacking for both non-IgG antibodies production and basic research.

Advantages of Non-IgG Therapeutic Antibodies

Despite confronted with difficulties and challenges, non-IgG antibodies (mainly IgA and IgM) display some advantages over IgG antibody or a potential supplement therapy, especially for cases when IgG is less suitable or insufficient.

  • Non-IgG antibodies may perform better in terms of non-blood targets binding.
  • IgA and IgM predominantly exert their functions in dimeric or polymeric form.
  • Both monomeric and dimeric IgA antibodies can directly induce neutrophil migration, which means that neutrophils can be recruited by IgA than that by IgG, thus triggering more effective cytotoxicity. And IgM induces stronger complement dependent cytotoxicity.
  • The stronger binding ability of IgM. There are 10 binding domains for different targets of a pentameric IgM. And IgM can efficiently bind to low expression targets and highly glycosylated targets.
  • The number and location of glycosylation sites of non-IgG antibodies are different from IgG. More glycosylation sites and different location indicate more possibilities for modification.

Schematic representation of the human immunoglobulin subclasses. Fig.1 Schematic representation of the human immunoglobulin subclasses. (James, 2016)

Our Service

To discover more efficient therapeutic antibodies and provide more comprehensive services, Creative Biolabs has developed the exclusive Non-IgG Therapeutic Antibodies Platform based on our acquired experience and accumulated expertise. After years of efforts and concentrated study, we are confident in providing a full range of custom non-IgG therapeutic antibody (including therapeutic IgA, IgM, IgE, and IgY antibodies) discovery services for international clients with best strategies and professional solutions.


  • Diversity
    Diverse products and service are available for you to choose.
  • Customization
    Tailored products and service based on your specific demands.
  • Guarantee
    Good reputation in this field for many years, both products and services are reliable.
  • Superior service
    Seasoned technologies and professional scientific teams provide the best service with low-cost and high efficiency.


Q1: What does Creative Biolabs' Non-IgG Therapeutic Antibodies Platform provide?

A: Our Non-IgG Therapeutic Antibodies Platform provides a comprehensive range of custom non-IgG therapeutic antibody discovery services, including therapeutic IgA, IgM, IgE, and IgY antibodies. The services feature diversity, customization, reliability, and superior service from seasoned technologies and professional scientific teams.

Q1: What is the focus of Creative Biolabs' research?

A: We are dedicated to promoting human health research and have focused on the development of non-IgG antibodies for several years. The goal is to discover more efficient therapeutic molecules, and we provide a wide range of products and services for non-IgG therapeutic antibodies globally.

Q1: What should I do if I want to inquire about Creative Biolabs’ other Non-IgG Therapeutic Antibody Development Services?

A: You can contact our expert team directly. If you have specific and detailed service needs, you can directly request a quote. If not, you can send us a request and we will provide you with a customized solution.

Published Data

Title: A human IgM enriched immunoglobulin preparation, Pentaglobin, reverses autoimmune diabetes without immune suppression in NOD mice

Journal: Scientific Reports

Authors: Christopher S. Wilson, Emilee M. Hoopes, Alexander C. Falk, Daniel J. Moore
Abstract: The immune system of healthy individuals is capable of regulating autoimmunity through multiple mechanisms. In Type 1 Diabetes (T1D) we recently discovered natural IgM, although present at normal levels, is unable to perform its normal immunoregulatory function. Treating diabetic mice with IgM from healthy donors led to reversal of disease without immune depletion. To investigate the therapeutic potential of a human preparation of IgM, we administered an IgM-enriched preparation of immunoglobulin called Pentaglobin. Administration of Pentaglobin therapy reversed disease in diabetic NOD mice and boosted CD4 + Foxp3 + Tregs. Importantly, the impact of Pentaglobin on the immune system was limited to inhibiting beta cell destruction but was not immune depleting nor did it inhibit the immunization response to an irrelevant antigen. These findings indicate that inhibition of deleterious autoimmunity in T1D is possible while leaving protective immunity fully intact.

non-igg-therapeutic-antibodies-discovery-3 Pentaglobin, an immunoglobulin preparation enriched in human IgM, reverses diabetes in NOD mice.


If you are working on non-IgG antibody research or interested in non-IgG therapeutic antibodies, please feel free to contact us or for more detailed information.


  1. James, L.K. The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy. Current Allergy and Asthma Reports. 2016, 16: 15.

!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.

Online Inquiry
For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.






Stay Up To Date

© 2024 Creative Biolabs All Rights Reserved